DOWNERS GROVE, ILLINOIS -- April 3, 2020 -- Hirose, a leader in the design and manufacture of innovative connector solutions, is prioritizing and expediting orders to medical equipment manufacturers. Hirose's connectors are being used in medical equipment vital to the fight against COVID-19, including w. Hirose has been tasked with increasing connector output and lowering lead times of connectors used in life-saving medical equipment.

"With many critical medical devices in short supply, Hirose has been asked to increase our support to company's building medical equipment as part of the fight against COVID-19. Hirose has a long-standing tradition of serving the medical industry, and we are eager to do our part to meet the essential manufacturing needs during these challenging times," said Bill Kysiak, Product Marketing Manager for Hirose Electric USA. "Although part of a design effort we were working on well before the crisis, the pandemic has accelerated the production timetable. We have been tasked with increasing our production volume and lowering our lead times, which is our number one priority at this time."

Used in a wide variety of medical applications, Hirose connectors bring the latest in technological solutions and high reliability to meet stringent and evolving medical standards.

For more information on Hirose's medical connectors, visit: https://www.hirose.com/product/industry/Medical?lang=en

For more information about Hirose, visit www.hirose.com/us

ABOUT HIROSE ELECTRIC

Hirose Electric Co., Ltd. is a leading global supplier of innovative interconnects, with sales of over $1 billion to customers worldwide. Hirose employs advanced engineering services, superior customer support and worldwide manufacturing capabilities to provide value-based connector solutions for various industries including: industrial, telecommunication, consumer electronics, computer and automotive. More information can be found on Hirose Electric's corporate website at www.hirose.com

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedInPrint Article